Focused On-demand Library for Beta-nerve growth factor

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

This includes comprehensive molecular simulations of the receptor in its native membrane environment, paired with ensemble virtual screening that factors in its conformational mobility. In cases involving dimeric or oligomeric receptors, the entire functional complex is modelled, pinpointing potential binding pockets on and between the subunits to capture the full range of mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
P01138

UPID:
NGF_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P01138; A1A4E5; Q6FHA0; Q96P60; Q9P2Q8; Q9UKL8

BACKGROUND:
The Beta-nerve growth factor, essential for sympathetic and sensory neuron health, binds to receptors NTRK1 and NGFR to activate survival and growth pathways. Its precursor, proNGF, induces apoptosis and growth cone collapse, highlighting its complex role in neuron dynamics. Additionally, NGF interacts with lipids to modulate immune responses, illustrating its multifunctionality in biological systems.

THERAPEUTIC SIGNIFICANCE:
Given its critical role in hereditary sensory and autonomic neuropathy type 5, marked by significant sensory impairments, NGF presents a promising target for therapeutic intervention. Exploring NGF's function could lead to novel strategies for managing and treating neuropathic disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8123 of 8789